Article
Brochure
Executive Resource
Insight Hub
Ext. Publication
VideoState of Life Sciences in the US: Capital Concentrates as the Market Narrows
Valuation Services
Never miss a thing.
Sign up to receive our insights newsletter.
The U.S. life sciences sector entered the first half (H1) of 2026 with a striking divergence. Fewer companies are raising money, fewer patents are being published and activity in several major clinical trial markets is declining. At the same time, total private capital, merger and acquisition (M&A) value and public market activity are rising.
The result is not necessarily a shrinking industry but a more selective one. Capital is increasingly flowing to fewer companies, larger transactions and later-stage programs with differentiated clinical data, while early-stage ventures face a more challenging funding environment.
Weaver’s latest State of Life Sciences in the U.S. report examines these trends nationally and across four of the country’s most important life sciences markets: California, Texas, New York and Massachusetts. Together, the four states account for approximately half of U.S. interventional clinical trials, 88% of public life sciences companies and more than 75% of venture capital deployed in the sector.
H1 2026 Key Highlights
Innovation is shifting toward biotechnology. Patent publications declined 4.1% nationally, led by weakness in traditional pharmaceutical development. Biotechnology and genetic engineering patents, however, increased nearly 20%, reflecting continued movement toward gene therapy, cell therapy, antibody platforms and other biological modalities. Corporate patent filings declined while academic output remained comparatively stable.
Clinical trial growth is concentrated in later stages. National trial starts edged up 1.3% year over year, but California, Texas, New York and Massachusetts all posted declines. Phase 2 and other later-stage activity drove national growth while Phase 1 remained relatively flat, suggesting that funding is increasingly favoring programs that have already generated clinical data.
Private capital is flowing into fewer, larger deals. National life sciences deal count fell 18.2% year over year. Capital raised increased 23.8% to $29 billion. Average deal size increased by approximately 50%, and pre-seed deal activity declined 43.6%. Series B emerged as a particular area of strength, reinforcing the shift toward companies that have moved beyond the earliest stages of development.
M&A value surged as mega deals returned. Disclosed M&A value more than doubled to $247.2 billion, fueled by 22 transactions valued above $2.5 billion. Q2 alone generated $102.4 billion in disclosed deal value, the largest quarter on record. Yet earnout structures remain common, creating a significant distinction between announced transaction values and consideration ultimately realized by sellers.
Public markets showed renewed strength. The XBI Biotech ETF gained 30.2% through June, and biopharma IPOs raised $5 billion across 13 offerings, already exceeding full-year totals for each year from 2022 through 2025.
Life Sciences Market Trends Across Four Key States
The national numbers tell only part of the story. California, Texas, New York and Massachusetts occupy different positions in the life sciences development cycle, and their H1 results illustrate how unevenly current market forces are playing out.
California remains the country’s largest life sciences market, with patent activity nearly flat even as innovation shifts toward biotechnology and genetic engineering. Texas continues to play an important role as a clinical trial site, but growth in Texas-sponsored Phase 1 and device trials suggests the state may be developing a larger role in originating clinical programs. New York combines strong academic medical center research with major pharmaceutical headquarters, contributing to a relatively balanced innovation-to-commercialization profile. Massachusetts experienced the steepest decline in clinical trial starts among the four states even as its companies continued to attract significant investment and acquisition interest.
What Life Sciences Market Trends Mean for Investors and Companies
Taken together, the data points to a life sciences market that has capital available but is becoming more selective about where that capital goes. Investors are favoring larger and more mature opportunities, M&A activity is increasingly influenced by mega-deals and public markets are showing signs of reopening. At the same time, declining early-stage funding and patent activity raise longer-term questions about the pipeline of companies and discoveries that will feed future growth.
Download the State of Life Sciences in the U.S. report
©2026
